



# IgG light chain (SB62a): sc-69831

## BACKGROUND

The basic structural unit of most mammalian antibodies is a glycoprotein composed of four polypeptide chains—two light chains and two heavy chains, which are connected by disulfide bonds. Each light chain is composed of two domains, one variable domain (VL) and one constant domain (CL). The variable region genes encoding immunoglobulin  $\kappa$  and  $\lambda$  chains are assembled from three DNA segments, the V, C and J genes. Human  $\kappa$  light chain genes map to chromosome 2 and the human  $\lambda$  light chain genes map to chromosome 22.  $\kappa$  gene recombination can precede  $\lambda$  gene recombination during B cell ontogeny and only a single light chain type is expressed in individual B cells.

## REFERENCES

1. Winzer, M., Ruppert, M., Baretton, G., Quast, U. and Wolff, H.H. 1992. Bullous poikilodermatic amyloidosis of the skin with junctional bulla development in IgG light chain plasmacytoma of the  $\lambda$  type. *Histology, immunohistology and electron microscopy. Hautarzt* 43: 199-204.
2. Claydon, M.A., Gordon, D.B., Garner, G.V. and Lord, G.A. 1995. A partial sequence of an IgG light chain using continuous flow HPLC-FAB mass spectroscopy. *Biochem. Soc. Trans.* 23: 633S.
3. Król, M. 2003. Comparison of various implicit solvent models in molecular dynamics simulations of immunoglobulin G light chain dimer. *J. Comput. Chem.* 24: 531-546.
4. Król, M. 2003. Analysis of the effect of electrostatic energy truncation in molecular dynamics simulations of immunoglobulin G light chain dimer. *J. Mol. Model.* 9: 316-324.
5. Król, M., Roterman, I., Piekarska, B., Konieczny, L., Rybarska, J., Stopa, B. and Spólnik, P. 2005. Analysis of correlated domain motions in IgG light chain of immunological signal transduction. *Proteins* 59: 545-554.
6. Nakatsuka, A., Maeshima, Y., Sarai, A., Yanai, H., Sugiyama, H., Yamasaki, Y. and Makino, H. 2005. A case of monoclonal immunoglobulin light- and heavy-chain deposition disease exhibiting atypical deposition with fibrillary structures, successfully treated with chemotherapy. *Clin. Nephrol.* 64: 221-227.
7. Drayson, M., Begum, G., Basu, S., Makkuni, S., Dunn, J., Barth, N. and Child, J.A. 2006. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. *Blood* 108: 2013-2019.
8. Giritch, A., Marillonnet, S., Engler, C., van Eldik, G., Botterman, J., Klimyuk, V. and Gleba, Y. 2006. Rapid high-yield expression of full-size IgG antibodies in plants coinfecting with noncompeting viral vectors. *Proc. Natl. Acad. Sci. USA* 103: 14701-14706.
9. Halimi, M., Dayan-Amouyal, Y., Kariv-Inbal, Z., Friedman-Levi, Y., Mayer-Sonnenfeld, T. and Gabizon, R. 2006. Prion urine comprises a glycosaminoglycan-light chain IgG complex that can be stained by Congo red. *J. Virol. Methods* 133: 205-210.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## SOURCE

IgG light chain (SB62a) is a mouse monoclonal antibody raised against light chain of rabbit origin.

## PRODUCT

Each vial contains 100  $\mu$ g IgG<sub>2b</sub> in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

## APPLICATIONS

IgG light chain (SB62a) is recommended for detection of IgG light chain of rabbit origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000).

Molecular Weight of IgG light chain: 25 kDa.

## STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.